Functional Drug Screening in the Era of Precision Medicine

Napoli, Giulia C.; Figg, William D.; Chau, Cindy H.

doi:10.3389/fmed.2022.912641

Cited by 10 publications

(8 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to low response rate to the approved anti-cancer treatments for OSCC, high rate of recurrence, and the limited options of treating these patients, the possibility of applying personalized treatment testing represents a large step towards improving patient survival. Several models have been developed towards developing a personalized treatment testing, such as spheroids, organoids, histocultures, microfluidic chips, and zebrafish larvae [31] . All of these models have both advantages and limitations, however most face the major problem of lack of validation with a direct comparison with the patients’ response.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma

Wahbi¹,

Korelin²,

Sieviläinen³

et al. 2023

Translational Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma

Wahbi¹,

Korelin²,

Sieviläinen³

et al. 2023

Translational Oncology

View full text Add to dashboard Cite

“…Finally, functional phenotype analysis using exvivo drug screening has entered clinical trials as a selection tool in a few cutting-edge centres [90].…”

Section: Next-generation Multimodal Diagnostics For Trial Inclusionmentioning

confidence: 99%

“…Finally, functional phenotype analysis using ex‐vivo drug screening has entered clinical trials as a selection tool in a few cutting‐edge centres [90]. Here, patient‐derived cells are tested for sensitivity to available cancer drugs for treatment selection in late‐stage patients.…”

Section: Next‐generation Multimodal Diagnostics For Trial Inclusionmentioning

confidence: 99%

High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond

Edsjö,

Russnes,

Lehtiö

et al. 2024

J Intern Med

View full text Add to dashboard Cite

In the last decades, the development of high‐throughput molecular assays has revolutionised cancer diagnostics, paving the way for the concept of personalised cancer medicine. This progress has been driven by the introduction of such technologies through biomarker‐driven oncology trials. In this review, strengths and limitations of various state‐of‐the‐art sequencing technologies, including gene panel sequencing (DNA and RNA), whole‐exome/whole‐genome sequencing and whole‐transcriptome sequencing, are explored, focusing on their ability to identify clinically relevant biomarkers with diagnostic, prognostic and/or predictive impact. This includes the need to assess complex biomarkers, for example microsatellite instability, tumour mutation burden and homologous recombination deficiency, to identify patients suitable for specific therapies, including immunotherapy. Furthermore, the crucial role of biomarker analysis and multidisciplinary molecular tumour boards in selecting patients for trial inclusion is discussed in relation to various trial concepts, including drug repurposing. Recognising that today's exploratory techniques will evolve into tomorrow's routine diagnostics and clinical study inclusion assays, the importance of emerging technologies for multimodal diagnostics, such as proteomics and in vivo drug sensitivity testing, is also discussed. In addition, key regulatory aspects and the importance of patient engagement in all phases of a clinical trial are described. Finally, we propose a set of recommendations for consideration when planning a new precision cancer medicine trial.

show abstract

“…The mutations induced in GEMMS to produce disease phenotypes do not precisely capture the diversity of human disease phenotypes or subtypes. In addition, GEMMS are generally seen as poor predictors of clinical success [ 61 ].…”

Section: Clinical Implications and Future Prospectivementioning

confidence: 99%

Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine

Spagnol

Sensi

Tommasi

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) has the highest mortality rate of all gynecological malignancies due to the high prevalence of advanced stages of diagnosis and the high rate of recurrence. Furthermore, the heterogeneity of OC tumors contributes to the rapid development of resistance to conventional chemotherapy. In recent years, in order to overcome these problems, targeted therapies have been introduced in various types of tumors, including gynecological cancer. However, the lack of predictive biomarkers showing different clinical benefits limits the effectiveness of these therapies. This requires the development of preclinical models that can replicate the histological and molecular characteristics of OC subtypes. In this scenario, organoids become an important preclinical model for personalized medicine. In fact, patient-derived organoids (PDO) recapture tumor heterogeneity with the possibility of performing drug screening. However, to best reproduce the patient’s characteristics, it is necessary to develop a specific extracellular matrix (ECM) and introduce a tumor microenvironment (TME), which both represent an actual object of study to improve drug screening, particularly when used in targeted therapy and immunotherapy to guide therapeutic decisions. In this review, we summarize the current state of the art for the screening of PDOs, ECM, TME, and drugs in the setting of OC, as well as discussing the clinical implications and future perspectives for the research of OC organoids.

show abstract

Functional Drug Screening in the Era of Precision Medicine

Cited by 10 publications

References 122 publications

Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma

Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma

High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond

Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine

Contact Info

Product

Resources

About